1,3-Diarylpyrazolyl-acylsulfonamides as Potent Anti-tuberculosis Agents Targeting Cell Wall Biosynthesis in Mycobacterium tuberculosis

Spirocycle MmpL3 Inhibitors with Improved hERG and Cytotoxicity Profiles as Inhibitors of Mycobacterium tuberculosis Growth

(2021) Peter C. Ray et al.   ACS Omega

Telacebec (Q203), a New Antituberculosis Agent

(2020) Veronique R. de Jager et al.   NEW ENGLAND JOURNAL OF MEDICINE

Synthesis, Structure Activity Relationship and Mechanistic Studies of Aminoquinazolinones Displaying Antimycobacterial Activity

(2020) Jessica N. Akester et al.   ACS Infectious Diseases

Development of Macozinone for TB treatment: An Update

(2020) Vadim Makarov et al.   Applied Sciences-Basel

First time in human (FTIH) study and prediction of early bactericidal activity for GSK3036656, a potent Leucyl - tRNA synthetase inhibitor for tuberculosis treatment

(2019) David Tenero et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Synthesis and biological evaluation of aryl-oxadiazoles as inhibitors of Mycobacterium tuberculosis

(2018) Maria Angeles Martinez-Grau et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Cholesterol and fatty acids grease the wheels of Mycobacterium tuberculosis pathogenesis

(2018) Kaley M Wilburn et al.   Pathogens and Disease

Discovery and Structure–Activity-Relationship Study of N-Alkyl-5-hydroxypyrimidinone Carboxamides as Novel Antitubercular Agents Targeting Decaprenylphosphoryl-β-d-ribose 2′-Oxidase

(2018) Sangmi Oh et al.   JOURNAL OF MEDICINAL CHEMISTRY

Bioluminescent Reporters for Rapid Mechanism of Action Assessment in Tuberculosis Drug Discovery

(2016) Krupa Naran et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Bedaquiline and multidrug-resistant tuberculosis: a systematic and critical analysis of the evidence

(2016) Emanuele Pontali et al.   EUROPEAN RESPIRATORY JOURNAL

The Inosine Monophosphate Dehydrogenase, GuaB2, Is a Vulnerable New Bactericidal Drug Target for Tuberculosis

(2016) Vinayak Singh et al.   ACS Infectious Diseases

Design and synthesis of novel anti-tuberculosis agents from the celecoxib pharmacophore

(2015) Santosh B. Salunke et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Respiratory Flexibility in Response to Inhibition of CytochromecOxidase in Mycobacterium tuberculosis

(2014) Kriti Arora et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

The Cyclic Peptide Ecumicin Targeting ClpC1 Is Active against Mycobacterium tuberculosis In Vivo

(2014) Wei Gao et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Mycobacterium tuberculosis Metabolism

(2014) D. F. Warner   Cold Spring Harbor Perspectives in Medicine

Evolution of ADME Science: Where Else Can Modeling and Simulation Contribute?

(2013) Dennis A. Smith   MOLECULAR PHARMACEUTICS

Glucose Phosphorylation Is Required for Mycobacterium tuberculosis Persistence in Mice

(2013) Joeli Marrero et al.   PLoS Pathogens

Synthesis and in vitro anticancer and antitubercular activity of diarylpyrazole ligated dihydropyrimidines possessing lipophilic carbamoyl group

(2012) Rama Krishna Yadlapalli et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Discovery and development of SQ109: a new antitubercular drug with a novel mechanism of action

(2012) Katherine A Sacksteder et al.   Future Microbiology

Nonsteroidal anti-inflammatory drug sensitizes Mycobacterium tuberculosis to endogenous and exogenous antimicrobials

(2012) B. Gold et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Linezolid in the Treatment of Multidrug‐Resistant Tuberculosis

(2009) G. F. Schecter et al.   CLINICAL INFECTIOUS DISEASES

Mycobacterium tuberculosis Is Able To Accumulate and Utilize Cholesterol

(2009) A. Brzostek et al.   JOURNAL OF BACTERIOLOGY

Nutrient acquisition by mycobacteria

(2008) M. Niederweis   MICROBIOLOGY-SGM